Koptherapeutics
The startup develops Antisense Oligonucleotide (AON) therapy to selectively silence cancer-causing genes by targeting the translation process of specific DNA sequences into disease-causing proteins. This approach minimizes toxicity by allowing the drug to focus on cancer cells while sparing normal cells, thereby reducing side effects associated with traditional cancer treatments.
Traction –/10
Vancouver, Canada · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops Antisense Oligonucleotide (AON) therapy to selectively silence cancer-causing genes by targeting the translation process of specific DNA sequences into disease-causing proteins. This approach minimizes toxicity by allowing the drug to focus on cancer cells while sparing normal cells, thereby reducing side effects associated with traditional cancer treatments.